Popular Articles

Cancer Center Leads Breakthrough Clinical Trial: Cancer Vaccine For First Time Shows Promise Against Melanoma
A recent clinical trial - led by Goshen Center for Cancer Care - has yielded promising results for the future use of a cancer vaccine. One of the first studies to prove vaccines might have a medical benefit against cancer, study results found the new cancer vaccine doubled the response rate for tumor shrinkage as well as delayed the progression of cancer in patients with metastatic melanoma.

Positive Outcome Reached At 16 Weeks For Avexa's ATC Phase III Trial
Avexa Limited (ASX:AVX) announced that the Data Safety Monitoring Board (DSMB) met today to review the 16 week data from Avexa"s apricitabine (ATC) Phase III clinical trial. The DSMB reviewed the data and recommended continuation of the study with the 800mg dose. Patients taking the 1200mg dose will be transitioned to the optimum 800mg dose to continue their therapy.
News of the day
Bill Would Allow Federal Funding For Needle Exchange Programs
House Democrats on Friday as part of a spending measure to fund the Departments of Labor and HHS for fiscal year 2010, "unveiled legislation to lift a ban on federal funding for needle-exchange programs, a shift to try to reduce [HIV infections] but one that will probably spark a fight," Reuters/Boston Globe reports (7/11). The ban has been included in the annual spending bill in previous years. House Appropriations Committee Chair David Obey (D-Wis.) said, "Scientific studies have documented that needle exchange programs, when implemented as part of a comprehensive prevention strategy, are an effective public health intervention for reducing [HIV] infections and do not promote drug use" (Reuters, Pelofsky, 7/10). "The move is in keeping with a pledge [President] Obama made during the primaries to remove the prohibition on such funding, although the ban was carried in his budget request this year," CQ Today reports (Wolfe, 7/10). However, "Republicans are girding for a fight over the ban and lawmakers could try to restore it as the legislation moves through the House during the next two weeks," according to Reuters (7/10). The bill also addresses sex education and "appears to continue Democrats" slow march away from funding abstinence-only sex education," CQ reports (7/10).
Endocrinology

Bovie Medical Corporation Announces 510K Submission To The FDA For Its BOSS Soft Tissue Coagulation Device

Bovie Medical Corporation (the "Company") (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, announced a 510K submission to the FDA seeking pre-market clearance for Bovie"s BOSS for surgical applications where soft tissue bipolar coagulation is desired. The BOSS is the latest generation device based on Bovie"s saline enhanced sintered steel technology. The BOSS delivers RF energy simultaneously with saline to perform coagulation of soft tissue and bone, with minimal smoke, charring and sticking of tissue as well as reduced blood loss. Saline enhanced surgeries reduce operating time while improving post-operative outcomes and shortens recovery time. The BOSS will primarily be targeted towards orthopedic hip and knee reconstruction surgeries, which are significant markets, with over 1.3 million procedures performed in the United States annually. These procedures represent large and growing markets due to a more active and aging population. The worldwide market is expected to exceed $500 million in 2009. Andrew Makrides, president of Bovie, stated, "In today"s economic environment, where controlling medical costs is important, the BOSS technology meets the needs of patients, surgeons and hospitals. Reduced blood loss, shortened operating and recovery time makes the BOSS a technology product that targets a large and growing market." For further information about the Company"s current and new products, please refer to the Investor Relations section of Bovie"s website http://www.boviemedical.com. Bovie Medical Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):